Details About Generic Salt ::  Ticarci1

Main Medicine Class:: Antibiotic,penicillin   

(TIE-car-sill-in/CLAV-you-luh-nate)

Timentin

Class: Antibiotic/penicillin

 

Drugs Class ::

 Action Ticarcillin inhibits bacterial cell wall mucopeptide synthesis. Clavulanate lactamase enzymes commonly found in microorganisms resistant to ticarcillin.

Indications for Drugs ::

 Indications Treatment of bacterial septicemia, skin and skin structure infections, lower respiratory tract infections, bone and joint infections, genitourinary and gynecologic infections, and intra-abdominal infections caused by susceptible strains of bacteria.

Drug Dose ::

 Route/Dosage

Systemic and Urinary Tract Infections

ADULTS & CHILDREN ³ 60 KG: IV 3.1 g q 4–6 hr. ADULTS & CHILDREN < 60 KG: IV 200–300 mg/kg/day in divided doses q 4–6 hr.

Gynecologic Infections

ADULTS: IV 200–300 mg/kg/day in divided doses q 4–6 hr.

Contraindication ::

 Contraindications Hypersensitivity to penicillin.

Drug Precautions ::

 Precautions

Pregnancy: Category B. Lactation: Excreted in breast milk. Bleeding abnormalities: Hemorrhagic manifestations associated with abnormalities of coagulation tests (bleeding time, prothrombin time, platelet aggregation) may occur. Abnormalities should revert to normal once drug is discontinued. Hypersensitivity: Reactions range from mild to life-threatening. Administer cautiously to cephalosporin-sensitive patients due to possible cross-reactivity. Hypokalemia: Ticarcillin has rarely decreased potassium levels. Pseudomembranous colitis: May occur due to overgrowth of clostridia. Renal insufficiency: Dosage and interval adjustments necessary. Sodium content: Powder for injection contains 4.75 mEq Na/gram of ticarcillin. Superinfection: May result in bacterial or fungal overgrowth of non-susceptible organisms.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CV: Deep vein thrombosis; vein irritation; phlebitis. CNS: Neurotoxicity (lethargy, neuromuscular irritability and seizures). DERM: Rash; pruritis; urticaria; ecchymosis. GI: Nausea; vomiting; abdominal pain or cramp; diarrhea; pseudomembranous colitis. GU: Elevated creatinine or BUN; vaginitis. HEMA: Anemia; hemolytic anemia; thrombocytopenia; eosinophilia; leukopenia; ranulocytopenia; neutropenia; prolongation of bleeding and prothrombin time. HEPA: Transient hepatitis; cholestatic jaundice. META: Elevated serum alkaline phosphatase; hypernatremia; reduced serum potassium. OTHER: Hypersensitivity reactions; pain at site of injection; hematomas; hyperthermia.

Drug Mode of Action ::  

 Action Ticarcillin inhibits bacterial cell wall mucopeptide synthesis. Clavulanate lactamase enzymes commonly found in microorganisms resistant to ticarcillin.

Drug Interactions ::

 Interactions

Anticoagulants: May increase bleeding risks of anticoagulant by prolonging bleeding time. Chloramphenicol: Synergism or antagonism may develop. Contraceptives, oral: May reduce efficacy of oral contraceptives. Use additional form of contraception during ticarcillin/clavulanate therapy. Erythromycin: Synergism or antagonism may develop. Heparin: May increase bleeding risks of heparin by prolonging bleeding time. Probenecid: May increase ticarcillin levels. Sodium bicarbonate: Ticarcillin/clavulanate is incompatible with sodium bicarbonate; not recommended as diluent. Tetracyclines: May impair bactericidal effects of ticarcillin/clavulanate. INCOMPATIBILITIES: Aminoglycosides, parenteral: May inactivate aminoglycosides in vitro; o not mix in same IV solution. May be used in combination for synergy.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Assess results of AST & ALT, H&H, BUN and creatinine studies at appropriate intervals during therapy.
• Send urine and culture and sensitivity specimens to lab. Therapy may be initiated before results are received, but cultures should be collected prior to drug therapy.
• Request WBC and differential counts prior to initiation of therapy and at least weekly during therapy.
• Perform periodic hemoccult tests on stool.
• Monitor and record skin integrity. Report ecchymosis, bleeding and rashes.
• Assess neurologic status and report lethargy and irritability.
• Assess GI status and report changes in appetite or bowel habits. If patient has diarrhea, consider possibility of pseudomembranous colitis.
• Assess GU status and report hematuria, oliguria and proteinuria.
• Monitor data throughout therapy and report abnormalities to physician.
• Monitor I&O and report imbalances to physician. Ensure adequate fluid intake, especially if client has diarrhea episodes.
• Assess IV site regularly and report signs of vein irritation to physician.
• If pain and induration occur at injection site, apply ice pack.
• Monitor for signs of superinfection.

OVERDOSAGE: SIGNS & SYMPTOMS   Neuromuscular hyperexcitability, seizures

Drug Storage/Management ::

 Administration/Storage

• To reconstitute: Add approximately 13.0 ml of Sterile Water for Injection or Sodium Chloride Injection. Then dilute further to concentrations of 10–100 mg/ml with NaCl, 5% Dextrose or Lactated Ringer’s.
• Administer IV over 30 min by direct infusion or by piggyback.
• Discontinue other solutions while this drug is being infused via piggy-back.
• Do not mix sodium bicarbonate, gentamicin, amikacin or tobramycin in same IV solution.
• Store concentrated stock solution (200 mg/ml) no longer than 6 hr at room temperature or 72 hr under refrigeration.
• Store concentrations of 10–100 mg/ml in Sodium Chloride for Injection or Lactated Ringer’s no longer than 24 hr at room temperature; 7 days under refrigeration or 30 days frozen. Store solutions made with 5% extrose no longer than 24 hr at room temperature, 3 days under refrigeration or 7 days frozen.
• Thaw premixed, frozen solutions at room temperature or in refrigerator.
• Do not immerse in water baths or microwave to thaw.
• After thawing, store refrigerated no longer than 7 days or 24 hr at room temperature.
• Do not refreeze.

Drug Notes ::

 Patient/Family Education

• Advise patient to report rash, hives, fever, itching, severe diarrhea, shortness of breath, wheezing, black tongue, sore throat, nausea, vomiting, fever, swollen joints, unusual bleeding or bruising.
• Explain that intermittent urinalysis may be required several months after treatment.
• Tell diabetic patients to use Clinistix or Tes-tape for urine monitoring. Solutions used for urine glucose testing may indicate false-positive results if taking penicillin therapy over period of time.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.